Compare BOSC & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOSC | IGC |
|---|---|---|
| Founded | 1990 | 2005 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.7M | 31.5M |
| IPO Year | 2002 | 2005 |
| Metric | BOSC | IGC |
|---|---|---|
| Price | $4.69 | $0.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $8.00 | $5.25 |
| AVG Volume (30 Days) | 56.9K | ★ 967.4K |
| Earning Date | 05-28-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,271,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.06 |
| P/E Ratio | $8.97 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.52 | $0.24 |
| 52 Week High | $6.72 | $0.50 |
| Indicator | BOSC | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 52.13 | 64.72 |
| Support Level | $4.64 | $0.32 |
| Resistance Level | $5.07 | $0.44 |
| Average True Range (ATR) | 0.14 | 0.02 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 84.50 | 78.80 |
BOS Better Online Solutions Ltd is a provider of Intelligent Robotics and Supply Chain solutions for enterprises. The company manages its business in three reportable divisions: the Intelligent Robotics segment, the RFID Division segment, and the Supply Chain Solutions segment. The majority of revenue derives from Supply Chain Solutions which distributes electro-mechanical components, mainly to customers in the aerospace, defense, and other industries, and is a supply chain service provider for aviation customers that seek a comprehensive solution to their components-supply needs. Geographically company derives the majority of its revenue from Israel.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.